Jiangxi Synergy Pharmaceutical's API for Vonoprazan Fumarate Receives CDE Approval

Stock News02-25 18:40

Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that its active pharmaceutical ingredient (API) for Vonoprazan Fumarate has been approved by the Center for Drug Evaluation (CDE). The company confirmed the approval through the CDE's public registration platform for APIs, excipients, and packaging materials. Vonoprazan Fumarate is primarily indicated for the treatment of reflux esophagitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149930397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149930397","market":"sg","top_or_hot":-1,"title":"Jiangxi Synergy Pharmaceutical's API for Vonoprazan Fumarate Receives CDE Approval","media":"Stock News","content":"<p>Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that its active pharmaceutical ingredient (API) for Vonoprazan Fumarate has been approved by the Center for Drug Evaluation (CDE). The company confirmed the approval through the CDE's public registration platform for APIs, excipients, and packaging materials. Vonoprazan Fumarate is primarily indicated for the treatment of reflux esophagitis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Synergy Pharmaceutical's API for Vonoprazan Fumarate Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Synergy Pharmaceutical's API for Vonoprazan Fumarate Receives CDE Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-25 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that its active pharmaceutical ingredient (API) for Vonoprazan Fumarate has been approved by the Center for Drug Evaluation (CDE). The company confirmed the approval through the CDE's public registration platform for APIs, excipients, and packaging materials. Vonoprazan Fumarate is primarily indicated for the treatment of reflux esophagitis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1223082519.USD","symbol_name":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","start_time":0,"source_url":"","article_id":"1149930397","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149930397","pubTimestamp":1772016012,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that its active pharmaceutical ingredient (API) for Vonoprazan Fumarate has been approved by the Center for Drug Evaluation (CDE). The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300636":"同和药业","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","BK0239":"医药制造","LU1223082196.USD":"施罗德环球黄金A Acc","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK4017":"黄金","CDE":"科尔黛伦矿业"},"translate_title":"江西协同药业富马酸沃诺拉赞原料药获CDE批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300636":1,"CDE":1},"content_text":"Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that its active pharmaceutical ingredient (API) for Vonoprazan Fumarate has been approved by the Center for Drug Evaluation (CDE). The company confirmed the approval through the CDE's public registration platform for APIs, excipients, and packaging materials. Vonoprazan Fumarate is primarily indicated for the treatment of reflux esophagitis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149930397","isCrawlerRequest":true}